Key Drivers
- Liquidity buffer
- Profitability slump
- Rich valuation
AIAI Summary
VCEL's core question has shifted from financing to execution: with MACI still growing >20%, burn care accelerating, and BARDA adding visibility, the stock now hinges on proving durable margin expansion and sustained commercial momentum, because a miss on MACI growth, NexoBrid/BARDA delivery, or the 33 support level could quickly re-rate the valuation lower.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity buffer
- •Profitability slump
- •Rich valuation
VCEL has a very strong liquidity position and solid cash generation, but recent profitability has weakened and the stock still looks richly valued versus earnings power.
Price Behavior
Key Price Behavior Insights:
- •Lower-high pattern
- •Support holding
- •Reclaim needed
VCEL's last month price action is negative, with a lower-high/lower-low downtrend after repeated failures at $36.8–$36.9, though $32.8–$33.0 is currently acting as short-term support.
Sharp reversal after failing twice near $36.8–$36.9 and breaking below prior support
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Margin/loss beat
- •New contract visibility
Vericel delivered a strong Q1 with 30% revenue growth, a smaller-than-expected loss, and higher 2026 guidance, while new NexoBrid contract visibility adds another positive catalyst.
The latest results and guidance shift the outlook more bullishly for VCEL by reinforcing growth momentum and improving forward visibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings